文献速递神经肌肉病

贝克肌营养不良成人不同临床结局指标的敏感性:3年自然史研究

Sensitivity of Different Clinical Outcome Measures in Assessing Adults With Becker Muscular Dystrophy: A 3-Year Natural History Study.
PubMed 文献 · Neurology · 2025-09-05

3年随访仅起身速度(RFFv)SRM达-0.91;基线NSAA 10-32亚组中RFFv 1年SRM为-0.82,4级爬梯速度和NSAA 2年SRM分别为-1.03和-0.82。

要点

  • 3年随访仅RFFv对变化敏感(SRM -0.91)。
  • 基线NSAA 10-32亚组中RFFv 1年即敏感(SRM -0.82)。
  • NSAA可评估人数多于RFFv,或更适合门诊患者试验。

核心结论

  • RFFv是3年随访唯一对变化敏感的结局指标。
  • 按表型选择亚组可提高RFFv、4SCv和NSAA的敏感性。
  • NSAA可评估人数更多,可能更适合门诊患者临床试验。

研究设计与样本

  • 每年评估功能测试和肺功能,每两年评估超声心动图。
  • 计算年均变化值和标准化反应均值(SRM),SRM≥0.80视为高敏感性。

主要发现

  • 3年随访RFFv的SRM为-0.91(n=16),其他指标各时间点SRM均<0.8。
  • 功能亚组(基线NSAA 10-32)中,RFFv 1年SRM为-0.82(n=10)。
  • 功能亚组中4SCv 2年SRM为-1.03(n=11),NSAA 2年SRM为-0.82(n=13)。
  • 基因亚组间丧失行走年龄无显著差异。
  • 上肢和肺功能在丧失行走后仍保留,心脏功能下降与骨骼肌功能无关。

关键数值与推荐

  • SRM≥0.80定义为高敏感性。
  • 分析亚组包括外显子45-47缺失、影响nNOS结合位点的变异、基线NSAA 10-32。
  • 3年随访RFFv的SRM为-0.91(n=16)。
  • 功能亚组RFFv 1年SRM为-0.82(n=10)。
  • 功能亚组4SCv 2年SRM为-1.03(n=11),NSAA 2年SRM为-0.82(n=13)。

临床怎么用

  • 在贝克肌营养不良成人临床试验中,可优先考虑RFFv作为3年敏感终点。
  • 针对门诊患者,NSAA可评估人数更多,可能更适合作为主要终点。
  • 通过基线NSAA 10-32选择表型亚组,可提高短期试验的敏感性。

局限性

  • 研究为自然史观察,非干预性试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Slow and highly variable disease progression in Becker muscular dystrophy (BMD) stresses the need to develop sensitive outcome measures for clinical trials. We evaluated responsiveness of different outcome measures in adult patients with BMD over 3 years and explored if the sensitivity of outcome measures can be increased by selecting on phenotype or genotype. METHODS: Genetically confirmed patients with BMD were recruited via the Dutch Dystrophinopathy Database. Functional tests included North Star Ambulatory Assessment (NSAA), Timed Tests, Performance of the Upper Limb version 1.2, and pulmonary function yearly and echocardiography biennially. Mean changes and standardized response means (SRMs) were calculated per year. Outcome measures with SRM ≥0.80 were considered to have a high responsiveness to change. Two genetic subgroups-deletion of exons 45-47 and variants affecting the neuronal nitric oxide synthesis (nNOS) binding site-and one functional subgroup-NSAA between 10 and 32 at baseline-were analyzed separately. RESULTS: Thirty-six patients with BMD were included (mean age 41.2 years, range 18.6-67.3, 27 ambulant at baseline). A high responsiveness was observed for the rise from floor velocity (RFFv) at 3-year follow-up (SRM -0.91, n = 16), while the SRMs for the other outcome measures were <0.8 at all time points. In the functional subgroup, a high responsiveness was observed for RFFv at 1-year follow-up (SRM -0.82, n = 10), along with 4-stair climb velocity (4SCv) (SRM -1.03, n = 11) and NSAA (SRM -0.82, n = 13) at 2-year follow-up. Genetic subgroups did not significantly differ in age at loss of ambulation (LoA). Upper limb and pulmonary function were preserved beyond LoA. Decline of cardiac function was independent of skeletal muscle function. DISCUSSION: RFFv was the only outcome measure sensitive to change at 3-year follow-up. Selecting on phenotype resulted in a high responsiveness for RFFv at 1-year follow-up and for 4SCv and NSAA at 2-year follow-up. NSAA could be performed in more participants compared with RFFv and therefore seems preferable in clinical trials for ambulant patients. Despite limitations in sample size, the results suggest that clinical trials in the ambulant population could be enriched by selecting on phenotype.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Schrama EJ, Koeks Z, Van De Velde NM, et al. Sensitivity of Different Clinical Outcome Measures in Assessing Adults With Becker Muscular Dystrophy: A 3-Year Natural History Study. Neurology. 2025. PMID: 40911807. doi:10.1212/WNL.0000000000214071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。